Application

18504778 · ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS

Filed 2023-11-08 · Granted · Patent 12370195 (2025-07-29) The official file ↗The patent and its PDF ↗ · Art unit 1622 · Examiner Paul V Ward Easy · CPC A61K 31/506 · ACLARIS THERAPEUTICS, INC. · DLA Piper LLP (US)/Pittsburgh

Office actions

first was Restriction requirement

RCEs

no appeal

To first action

8.2 mo

to disposition 20.7 mo

Statutes raised

112 DP

2 actions read

Unlock the prosecution timelineIncluded in Pro, from $29 a month. Cancel any time.